Jane Street Group LLC Reduces Position in scPharmaceuticals Inc. (NASDAQ:SCPH)

Jane Street Group LLC trimmed its holdings in scPharmaceuticals Inc. (NASDAQ:SCPH) by 46.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,485 shares of the company’s stock after selling 20,206 shares during the quarter. Jane Street Group LLC’s holdings in scPharmaceuticals were worth $107,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. BNP Paribas Financial Markets boosted its position in shares of scPharmaceuticals by 116.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after acquiring an additional 3,101 shares during the last quarter. Captrust Financial Advisors raised its stake in scPharmaceuticals by 32.2% during the third quarter. Captrust Financial Advisors now owns 18,539 shares of the company’s stock worth $85,000 after purchasing an additional 4,513 shares during the period. MetLife Investment Management LLC boosted its holdings in scPharmaceuticals by 135.0% in the 3rd quarter. MetLife Investment Management LLC now owns 16,974 shares of the company’s stock valued at $77,000 after purchasing an additional 9,752 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of scPharmaceuticals by 15.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company’s stock valued at $375,000 after buying an additional 11,269 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of scPharmaceuticals during the 3rd quarter worth approximately $57,000. 89.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on SCPH shares. Craig Hallum decreased their price objective on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of scPharmaceuticals in a report on Thursday, November 14th.

scPharmaceuticals Price Performance

scPharmaceuticals stock opened at $3.38 on Wednesday. The company’s 50 day simple moving average is $3.54 and its 200-day simple moving average is $4.27. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. scPharmaceuticals Inc. has a 1 year low of $3.08 and a 1 year high of $6.54. The company has a market capitalization of $169.14 million, a price-to-earnings ratio of -1.78 and a beta of 0.11.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.